Navigation Links
Cornerstone Therapeutics to Present at BioCentury's 2009 Future Leaders in the Biotech Industry Conference
Date:3/31/2009

CARY, N.C., March 31 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at BioCentury's 16th Annual Future Leaders in the Biotech Industry Conference at 2:00 PM EDT on Thursday, April 2, 2009, at the Millennium Broadway Hotel & Conference Center in New York City.

A live audio and archived webcast of Cornerstone's presentation will be available through the Investor Relations section of the Company's website.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory market; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
2. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
3. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
4. Arno Therapeutics Reports 2008 Year-End Financial Results
5. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
8. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
9. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
10. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... Inc. has further extended its industry leading Biochemistry Services specifically targeting the ... cGMP techniques and methods for the biochemical and biosimilar characterization , ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 About Voice Recognition Biometrics Voice recognition ... against a stored voiceprint template. Acoustic features of ... tone are compared to distinguish between individual voices. ... most PCs already have a microphone and can ... biometrics are most likely to be deployed in ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
Breaking Biology News(10 mins):